Company Overview - PMGC Holdings Inc. announced a significant amendment to its License Agreement with MOA Life Plus Co., Ltd. for its subsidiary NorthStrive Biosciences, expanding the license rights to all uses in animal health, including feed additives [1][2] - NorthStrive Biosciences aims to capture new revenue streams from high-growth markets and lower barriers to entry in the animal health pharmaceutical sector [2][3] - The company focuses on developing advanced solutions to meet unmet needs in the U.S. animal health market [2][3] Industry Insights - The U.S. animal health market was valued at USD 12.65 billion in 2024 and is projected to grow at a CAGR of 7.97% from 2025 to 2030 [7] - Growth factors include innovations in companion animal pharmaceuticals, increasing pet adoption rates among millennials, and rising livestock populations in developing countries [7] - The amendment allows NorthStrive Biosciences to develop a comprehensive range of animal health products, which are essential for improving animal health and food security [7]

Group 1 - Univest Securities, LLC announced the closing of a registered direct offering for PMGC Holdings Inc., raising approximately $1.48 million through the sale of 294,450 shares at a price of $5.04 per share [1][2][3] - The offering was conducted under a shelf registration statement previously filed and declared effective by the SEC on February 7, 2025 [4] - PMGC Holdings Inc. is a diversified holding company with a portfolio that includes three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [7]

Core Viewpoint - PMGC Holdings Inc. has entered into a definitive agreement for a registered direct offering of 294,450 shares at a price of $5.04 per share, expected to raise approximately $1.48 million in gross proceeds [1][2]. Group 1: Offering Details - The offering involves the sale of common stock or pre-funded warrants, with the purchase price for the pre-funded warrants being the same as the shares, minus an exercise price of $0.001 per share [1]. - The transaction is anticipated to close on or about March 24, 2025, pending customary closing conditions [2]. - The company will have approximately 872,411 shares of common stock issued and outstanding following the offering [1]. Group 2: Regulatory Information - The offering is conducted under a shelf registration statement on Form S-3, which was declared effective by the SEC on February 7, 2025 [3]. - A final prospectus supplement and accompanying prospectus will be filed with the SEC, detailing the terms of the offering [3]. Group 3: Company Overview - PMGC Holdings Inc. is a diversified holding company that manages a portfolio through strategic acquisitions and investments across various industries [5]. - The company's portfolio includes three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [5].

Group 1 - PMGC Holdings Inc. has repurchased shares from certain existing shareholders who contacted the company directly, with details available in the Company's Form 8-K filings [1] - The company is open to considering additional share repurchases from other investors, depending on market conditions and other factors [1] - Shareholders interested in discussing potential repurchases are encouraged to contact the company directly in writing [2] Group 2 - PMGC Holdings Inc. is a diversified holding company that manages and grows its portfolio through strategic acquisitions, investments, and development across various industries [4] - The company's portfolio currently consists of three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [4] - The company is committed to exploring opportunities in multiple sectors to maximize growth and value [4]

Core Insights - Northstrive Biosciences Inc. has scheduled a pre-Investigational New Drug (pre-IND) meeting with the FDA on April 23, 2025, to discuss the path forward for filing an IND for EL-22 as a combination treatment with GLP-1 for muscle preservation [1][3][7] - EL-22 is a novel engineered probiotic designed to express myostatin on its surface, targeting the myostatin pathway to support muscle health, with preclinical studies showing significant improvements in models of Duchenne muscular dystrophy [2][4] - The company aims to file the IND application in 2025 and initiate clinical trials to evaluate the combination of EL-22 with GLP-1 receptor agonists for obesity treatment [3][4] Company Overview - Northstrive Biosciences Inc. is a subsidiary of PMGC Holdings Inc., focusing on the development of innovative aesthetic medicines, with EL-22 being its lead asset [4][5] - PMGC Holdings Inc. is a diversified holding company managing a portfolio through strategic acquisitions and investments across various industries [5]

Core Viewpoint - PMGC Holdings Inc. will implement a 1-for-7 reverse stock split effective March 10, 2025, to comply with Nasdaq listing requirements and enhance its market presence [1][3][4] Purpose of the Reverse Stock Split - The reverse stock split is essential for maintaining compliance with Nasdaq's listing requirements, which will enhance visibility and investor confidence, positioning the company for future growth [3] - There is no guarantee that the company will meet the minimum bid price requirement after the split [3] Nasdaq Rule Changes and Compliance Considerations - The reverse stock split is in response to recent Nasdaq rule changes aimed at ensuring compliance with listing requirements, particularly maintaining a stable share price above the minimum threshold [4] - The amendments highlight the company's commitment to addressing potential noncompliance issues proactively [4] Impact on Shareholders - Every 7 shares of common stock will consolidate into one share automatically, with no action required from shareholders [7] - Fractional shares will be rounded up to one full share for each fractional portion [7] - The trading symbol will remain "ELAB," but a new CUSIP number will be assigned [7] - Adjustments will be made to outstanding stock awards, options, and warrants to reflect the reverse split [7] Post-Split Share Structure - Post-split, approximately 577,000 shares of common stock will be issued and outstanding as of March 10, 2025 [9] - The total number of authorized shares will also decrease at the same 1-for-7 ratio as the issued and outstanding shares [9]

Core Viewpoint - PMGC Holdings Inc. will implement a 1-for-7 reverse stock split effective March 10, 2025, to comply with Nasdaq listing requirements and enhance its market presence [1][3]. Group 1: Purpose and Compliance - The reverse stock split is essential for PMGC to meet Nasdaq's listing requirements, thereby maintaining its visibility and investor confidence [3]. - Recent Nasdaq rule changes necessitate this action to ensure compliance, particularly regarding maintaining a stable share price above the minimum threshold [4]. Group 2: Impact on Shareholders - Every 7 shares of common stock will consolidate into one share automatically, with no action required from shareholders [7]. - Fractional shares will be rounded up to one full share, and the trading symbol will remain "ELAB" with a new CUSIP number assigned [7]. - Adjustments will be made to outstanding stock awards, options, and warrants to reflect the reverse split [7]. Group 3: Post-Split Structure - After the split, approximately 577,000 shares of common stock will be issued and outstanding [9]. - The total number of authorized shares will also decrease at the same 1-for-7 ratio, eliminating the need for shareholder approval [9].

Core Insights - PMGC Holdings Inc. has announced its annual sponsorship of TCA Venture Group's Orange County network for 2025, aiming to enhance its investment and M&A opportunities while supporting local business growth [1][5] - TCA Venture Group is recognized as one of the largest and most active angel investor networks in the U.S., having invested over $300 million in more than 525 companies since its inception in 1997 [2][4] - The collaboration with TCA is expected to provide PMGC with access to a vast network of over 400 seasoned investors and industry professionals, enhancing its acquisition strategy and portfolio expansion [4][5] Company Overview - PMGC Holdings Inc. is a diversified holding company managing a portfolio through strategic acquisitions and investments across various industries, currently comprising three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [6] - Northstrive Biosciences Inc. focuses on developing aesthetic medicines, particularly addressing obesity through innovative probiotic approaches [7] - PMGC Research Inc. is engaged in R&D, leveraging Canadian research grants to accelerate scientific discovery [7] - PMGC Capital LLC operates as a multi-strategy investment firm, targeting undervalued companies and assets for sustainable growth [7] TCA Venture Group Overview - TCA Venture Group, formerly known as Tech Coast Angels, has a history of over 25 years in funding early-stage companies across innovation-driven industries, having attracted an additional $2.2 billion in follow-on investments from venture capital firms [2][4] - TCA members provide not only capital but also mentorship, board representation, and strategic partnerships, contributing significantly to the entrepreneurial ecosystem in Southern California [4][8] - TCA has been ranked as the 2 U.S. angel investment network for funded deals and recognized for its network centrality by CB Insights [4]

Core Viewpoint - PMGC Holdings Inc. has announced an update on its capital structure, emphasizing its strong financial position and commitment to strategic priorities through its subsidiaries [1][2]. Capital Structure and Financial Position - As of February 25, 2025, PMGC's capital structure includes 4,042,295 common shares outstanding, 4,931 stock options with a weighted-average exercise price of $304 per share, and 979,814 warrants with a weighted-average exercise price of $4.91 per share [5]. - The company has zero debt, indicating a strong balance sheet [5]. - Recent capital raises include $8.0 million from an S-1 offering in September 2024 and approximately $1.9 million from a warrant inducement offering in January 2025 [5]. Subsidiaries and Business Focus - PMGC Holdings operates through three wholly owned subsidiaries: Northstrive Biosciences Inc., PMGC Research Inc., and PMGC Capital LLC [3]. - Northstrive Biosciences focuses on developing aesthetic medicines, particularly targeting obesity treatment with its lead asset, EL-22 [5]. - PMGC Research is dedicated to R&D, leveraging Canadian research grants and partnerships with universities to commercialize technologies [5]. - PMGC Capital is a multi-strategy investment firm that seeks undervalued companies and assets to drive sustainable growth [5].

NorthStrive A PMGC HOLDINGS COMPANY (NASDAQ: ELAB) PIONEERING AESTHETIC MEDICINE DISCLAIMERS & FORWARD LOOKING STATEMENTS Any farward-looling statement made by us is based upan the reasonable judgment of our management at the time such statement is made and speals only as of the date on which it is made. Factors or events that could cousse our actual results to differ may emerge from time to time, and it is not possible for us to predict all of the We undertake no obligation to update any forward-looking st ...